Sipai Health Technology (0314) H1 2024 earnings summary

Executive summary

• H1 2024 revenue fell 3.0% YoY to RMB2,363.780m; core revenue excluding medication distribution grew 5.5% to RMB2,280.0m.

• Gross profit rose 5.0% to RMB228.931m and gross margin increased to 9.7%; adjusted loss narrowed 47.4% to RMB29.694m.

• Medication distribution was strategically reduced, while Enterprise Health Insurance and Physician Research Assistance grew; strategy emphasized core healthcare businesses, efficiency, digitalization and the health insurance plus healthcare management model.

Financial highlights

• Revenue was RMB2,363.780m, down 3.0% YoY; cost of sales declined 3.8% to RMB2,134.8m and gross profit rose 5.0% to RMB228.931m.

• IFRS loss narrowed 14.5% to RMB74.651m; non-IFRS loss excluding share-based payment compensation was RMB28.794m versus RMB33.189m.

• Adjusted loss, excluding share-based payment compensation and non-recurring government grants, narrowed 47.4% YoY to RMB29.694m.

• Selling and marketing expenses fell 9.4% to RMB137.816m, administrative expenses fell 7.7% to RMB161.889m, and R&D expenses fell 37.1% to RMB15.013m.

• Other income and gains declined to RMB19.033m from RMB52.303m; government grants were RMB0.9m versus RMB23.224m a year earlier.

Outlook and guidance

• Enterprise Health Insurance growth momentum was expected to continue into H2 2024.

• Future liquidity needs were expected to be met from cash, cash equivalents and remaining Global Offering proceeds; operating cash generation was expected to develop as commercialized product sales grow.

• Unutilized Global Offering proceeds were planned for business expansion and technology R&D, with expected use in 2024 and no material change to planned allocations.